Abstract 3128
Background
Recurrent Respiratory papillomatosis (RRP) can result in significant morbidity due to effects on voice and breathing and often requires frequent debulking procedures, which can disrupt quality of life. Responses to current surgical and medical treatments are inconsistent and there are no systemic treatments proven to be consistently effective in managing this disease. Bevacizumab, an anti-angiogenic agent that targets the vascular endothelial growth factor (VEGF) has been used as systemic agent for the treatment of RRP. We present a retrospective analysis of safety, efficacy and clinical outcomes in thirteen patients who were treated with systemic bevacizumab.
Methods
We present a retrospective analysis of patients with severe RRP who received 10mg/kg or 15mg/kg systemic bevacizumab at 3 weekly intervals at a single academic tertiary care center. They were monitored for toxicity and response to treatment as measured by need for further surgical interventions and improvement of symptoms.
Results
Twelve patients received at least 2 doses of systemic bevacizumab for an average of 5 cycles. Overall the treatment was well tolerated with minimal side effects. The most common side effect was hypertension, which was experienced by 4 out of 12 patients. Two patients discontinued treatment due to side effects. One experienced grade 3 epistaxis and another patient developed hypertension and thrombocytopenia. Two other individuals tolerated treatment well however, therapy was suspended due to insurance denial. All patients reported an improvement in symptoms including, improved quality of voice and breathing as well as decreased cough. The average number of surgical interventions in the year prior to administration of systemic bevacizumab was 4, with most individuals requiring intervention at a frequency of 2-4 months. Following treatment, only 4 of the 12 patients required one surgical intervention.
Conclusions
Systemic bevacizumab appears to be a safe and well tolerated treatment option for patients with severe RRP. It demonstrates promising efficacy on symptoms including voice quality and improved breathing as well as decreased requirement for surgical therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2108 - Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase 3 study.
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3090 - Comparison of Immuno-Oncology (IO) Biomarkers in Adenocarcinoma (ACB), Urothelial Carcinoma (UCB) and Squamous Cell Carcinoma (SCCB) of the Bladder, with interim results from PURE01
Presenter: Daniele Raggi
Session: Poster Display session 3
Resources:
Abstract
5211 - Potential role of a clinical, taxonomical classification and RNA expression integrated signature to predict response to neoadjuvant platinum-based chemotherapy in muscle-invasive bladder cancer (MIBC) patients
Presenter: Albert Font
Session: Poster Display session 3
Resources:
Abstract
3206 - Hyperphosphatemia due to Erdafitinib (a Pan-FGFR Inhibitor) and Anti-tumor Activity Among Patients (Pts) with Advanced Urothelial Carcinoma (UC)
Presenter: Scott Tagawa
Session: Poster Display session 3
Resources:
Abstract
3110 - Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting
Presenter: Florian Roghmann
Session: Poster Display session 3
Resources:
Abstract
3564 - Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)
Presenter: Jean-Michel Lavoie
Session: Poster Display session 3
Resources:
Abstract
2760 - Comparative analysis of tumor mutational burden (TMB) prediction methods and its association with determinants of the tumor immune microenvironment of urothelial bladder cancer (UBC)
Presenter: Markus Eckstein
Session: Poster Display session 3
Resources:
Abstract
2513 - The Immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: clinical significance for pathological response and survival
Presenter: Elise Nassif
Session: Poster Display session 3
Resources:
Abstract
2835 - Genomic analysis of urothelial cancer and associations with treatment choice and outcome
Presenter: David Sarid
Session: Poster Display session 3
Resources:
Abstract
5763 - cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
Presenter: Sumanta Pal
Session: Poster Display session 3
Resources:
Abstract